Our Products

VPI-Benztropine

VPI-Benztropine is a synthetic compound resulting from the combination of the active portions of atropine and diphenhydramine. Benztropine possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism. Benztropine antagonizes the effect of acetylcholine. This decreases the imbalance between the neurotransmitters acetylcholine and dopamine, which may improve the symptoms of early Parkinson's disease.

VPI-Benztropine is recommended for all etiologic groups of parkinsonism - arteriosclerotic, postencephalitic, idiopathic and drug-induced. It can be effective at any stage of the disease, even when a patient has become bedridden. Often it is helpful in patients who have become unresponsive to other agents.

VPI-Benztropine
Proper Name Benztropine Mesylate Injection, USP
Brand Reference CogentinTM injectable
DIN 02486822
UPC 6 28804 00014 1
Strength 2 mg/2 mL
Dosage Form Solution
Format 10 x 2 mL
Therapeutic Class Antiparkinsonian Agent
Product Monograph
Product Code VBEN100
 

VPI-Ethacrynate Sodium

VPI-Ethacrynate Sodium injection belongs to a group of medicines called loop diuretics. Ethacrynate Sodium is administered to treat fluid retention (edema) and swelling that is caused by congestive heart failure, acute pulmonary oedema, renal oedema, hepatic cirrhosis with ascites or other medical conditions.

VPI-Ethacrynate Sodium
Proper Name Ethacrynate Sodium for injection, USP
Brand Reference Sodium Edecrin®
DIN 02462362
UPC 6 28804 00011 0
Strength 50 mg
Dosage Form Powder for Solution
Format 1
Therapeutic Class Saluretic – Diuretic Agent
Product Monograph
Product Code CVETH100
 

VPI-Ondansetron ODT

Ondansetron is a selective antagonist of the serotonin receptor subtype, 5-HT3. Its precise mode of action in the control of chemotherapy induced nausea and vomiting is not known. VPI-Ondansetron ODT (ondansetron) is indicated for:

  • the prevention of nausea and vomiting associated with emetogenic chemotherapy, including high dose cisplatin, and radiotherapy.
  • the prevention and treatment of post-operative nausea and vomiting. VPI-Ondansetron is available in 4mg and 8mg oral dissolve tablets (ODT)
VPI-Ondansetron ODT 4 mg
Proper Name Ondansetron orally disintegrating tablets
Brand Reference Zofran ODT®
DIN 02444674
UPC 6 28804 00012 7
Strength 4 mg
Dosage Form Tablet (Orally Disintegrating)
Format 10
Therapeutic Class Antiemetic (5-HT3 Receptor Antagonist)
Product Monograph
Product Code VONT101
VPI-Ondansetron ODT 8 mg
Proper Name Ondansetron orally disintegrating tablets
Brand Reference Zofran ODT®
DIN 02444682
UPC 6 28804 00013 4
Strength 8 mg
Dosage Form Tablet (Orally Disintegrating)
Format 10
Therapeutic Class Antiemetic (5-HT3 Receptor Antagonist)
Product Monograph
Product Code VONT102

Provincial Formulary Coverage

ListedPendingInterchangeableNo Coverage

Product Name BC AB SK MB ON QC NB PE NS NL
VPI-Benztropine DIN 02486822
VPI-Ethacrynate Sodium DIN 02462362
VPI-Ondansetron ODT 4 mg DIN 02444674
VPI-Ondansetron ODT 8 mg DIN 02444682